An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
Completed · Phase 3
Conditions studied: Schizophrenia
In brief
An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication. This study will accept both male and female participants that have completed study SEP361-308. This study will be held in approximately 24 study sites in North America. Participation in the study will be approximately up to 25 weeks.
Key facts
- Study ID
- NCT05741528
- Run by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- People needed
- 75
- Starts
- 2023-03-31
- Expected to finish
- 2024-09-23
- Last updated by the study team
- 2025-12-11
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Anaheim, California, United States
- Research Site — Bellflower, California, United States
- Research Site — Garden Grove, California, United States
- Research Site — Lemon Grove, California, United States
- Research Site — Santee, California, United States
- Research Site — Torrance, California, United States
- Research Site — Hollywood, Florida, United States
- Research Site — Miami, Florida, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Atlanta, Georgia, United States
- Research Site — Chicago, Illinois, United States
- Research Site — Gaithersburg, Maryland, United States
- Research Site — Berlin, New Jersey, United States
- Research Site — Charlotte, North Carolina, United States
- Research Site — Hickory, North Carolina, United States
- Research Site — Richardson, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.